Abciximab International Brand (Medicinal
Forms)
|
INDICATIONS AND DOSE:
|
Prevention of ischaemic cardiac complications in
patients undergoing percutaneous coronary intervention (specialist use only)
▶ INITIALLY BY INTRAVENOUS INJECTION
▶ Adult: Initially 250 micrograms/kg, to be given over 1 minute, then (by
intravenous infusion) 125 nanograms/kg/minute (max. per dose 10
micrograms/minute), to be started 10–60 minutes before percutaneous coronary
intervention and continue for 12 hours
Short-term prevention of myocardial infarction in patients
with unstable angina not responding to conventional treatment and who are
scheduled for percutaneous coronary intervention (specialist use only)
▶ INITIALLY BY INTRAVENOUS INJECTION
▶ Adult: Initially 250 micrograms/kg, to be given over 1 minute, then (by
intravenous infusion) 125 nanograms/kg/minute (max. per dose 10
micrograms/minute), to be started up to 24 hours before possible percutaneous
coronary intervention and continue infusion for 12 hours after intervention
|
CONTRA-INDICATIONS
|
Active internal bleeding . arteriovenous malformation or aneurysm .
haemorrhagic diathesis . hypertensive
retinopathy . intracranial neoplasm . intracranial or intraspinal surgery or
trauma within last 2 months . major surgery within last 2 months . severe
hypertension . stroke within last 2 years . thrombocytopenia . vasculitis
|
CAUTIONS
|
Discontinue if uncontrollable serious
bleeding occurs or emergency cardiac surgery needed (consult product literature
for details of procedures to minimize bleeding). elderly
|
SIDE-EFFECTS
|
Common or very common Back pain .
bleeding manifestations . bradycardia . chest pain . fever . headache . hypotension
. nausea . puncture site pain . thrombocytopenia . vomiting
▶ Rare Adult respiratory distress . cardiac tamponade .hypersensitivity
reactions
|
International Brands (Medicinal Forms)
|
|
Sr.
#
|
Brand Name
|
Dosage Form
|
Pack Size
|
Price
|
Manufacturer
|
|
1.
|
ReoPro
|
Solution
for injection-
Abciximab
2 mg per 1 ml
|
1
vial
|
£250.24
|
Janssen-Cilag
Ltd
|
Reference:
No comments:
Post a Comment